CTT Pharma CEO buys 3,500 shares at $0.05

CTT PHARMACEUTICAL HOLDINGS, INC.

Rhea-AI Filing Summary

CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reports that its CEO purchased 3,500 shares of CTTH on September 10, 2026 at a price of $0.05 per share in a direct, non-derivative open-market or private transaction. Following this purchase, the CEO directly holds 9,400,556 shares of CTTH. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 3,500 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 3,500 shs ($175.00)

Type	Security	Shares	Price	Value
Purchase	CTTH	3,500	$0.05	$175.00

Holdings After Transaction: CTTH — 9,400,556 shares (Direct)

Key Figures

Shares purchased: 3,500 shares Purchase price per share: $0.05 per share Shares held after transaction: 9,400,556 shares +2 more

5 metrics

Shares purchased 3,500 shares Non-derivative CTTH shares bought by the CEO on September 10, 2026

Purchase price per share $0.05 per share Price paid for CTTH shares in the CEO’s transaction

Shares held after transaction 9,400,556 shares CEO’s direct CTTH holdings following the purchase

Transactions reported 1 purchase Single non-derivative open-market or private transaction

Net buy/sell shares 3,500 shares net buy All reported activity on the Form 4

Key Terms

non-derivative, open-market or private transaction, Rule 10b5-1 trading plan

3 terms

non-derivative financial

"The CEO purchased 3,500 shares in a direct, non-derivative transaction"

open-market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CTTH report in this Form 4?

CTT PHARMACEUTICAL HOLDINGS, INC. reported that its CEO purchased 3,500 shares of CTTH on September 10, 2026 in a direct, non-derivative open-market or private transaction at $0.05 per share.

How many CTTH shares does the CEO hold after this transaction?

After the reported purchase, the CEO of CTT PHARMACEUTICAL HOLDINGS, INC. directly holds 9,400,556 CTTH shares.

What was the price paid per CTTH share in the CEO’s purchase?

The CEO’s purchase of CTTH shares was executed at $0.05 per share in a direct, non-derivative open-market or private transaction.

Was the CTTH insider trade made under a Rule 10b5-1 plan?

No. The report indicates that the CEO’s purchase of CTTH shares was not made pursuant to a Rule 10b5-1 trading plan.

What type of security was involved in the CTTH insider transaction?

The transaction involved non-derivative CTTH common shares, with 3,500 shares purchased on September 10, 2026, and total direct holdings increasing to 9,400,556 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 06:10 PM Accepted by SEC EDGAR 09/10/2026 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	09/10/2026		P		3,500	A	$0.05	9,400,556	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)